COO Ron-Bigger Shulamit Exercises Options and Sells $1.39M in Aktis Stock
AKTS sits 94% above its 52-week low of $14.72.
Summary
Aktis Oncology COO Ron-Bigger Shulamit exercised 50,000 options and sold all shares for $1.39 million, a routine monetization that reduces her direct stake but leaves substantial remaining holdings.
Key Events · Ownership and Investor Activity · AKTS
-
COO Exercises Options and Sells
Ron-Bigger Shulamit exercised 50,000 options at $3.66 and sold all shares in three open-market transactions for total proceeds of ~$1.39 million at prices between $27.13 and $28.75.
-
Financial Impact
The sale represents approximately 0.1% of Aktis's $1.57 billion market cap, a modest reduction in the COO's direct holdings to 217,888 shares.
-
Clinical Context
The transaction follows positive Phase 1b initiation and imaging data for AKY-2519 announced in May 2026, with the company's $538.5 million cash position funding operations into 2029.
-
Insider Sentiment
While insider selling can raise concerns, this appears to be a routine monetization of vested options rather than a signal of diminished confidence, given the COO's remaining equity stake and the company's strong clinical and financial position.
Analysis · AKTS · Life Sciences
Chief Operating Officer Ron-Bigger Shulamit exercised 50,000 options at $3.66 and immediately sold all resulting shares for roughly $1.39 million at prices between $27.13 and $28.75. The sale represents about 0.1% of the company's market cap — a notable but not alarming liquidation by a key insider. The transaction reduces her direct holdings to 217,888 shares, though she retains significant equity exposure. The sale comes amid positive clinical momentum for AKY-2519, with Phase 1b initiation and encouraging imaging data announced in May 2026, and a strong cash position of $538.5 million that funds operations into 2029. While insider selling always warrants attention, this appears to be a routine monetization of vested options rather than a signal of diminished confidence.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 29.4% of the 2796 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.03%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AKTS was trading at $28.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $14.72 to $34.19. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.